Loading
Life sciences · Journal article
Antibiotics · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Romania reports among the highest rates of carbapenem-resistant Gram-negative bacteria in the European Union, but patient-level data on healthcare-associated infections (HAIs) are scarce. We characterised carbapenem resistance, in-hospital outcomes, and carbapenem prescribing in a 24-month HAI cohort. Methods: This was a retrospective study of 315 patients with microbiologically confirmed HAI (2024–2025) at a tertiary infectious diseases hospital, contributing 243 Gram-negative isolates. Carbapenem resistance was determined by the hospital laboratory; extensively drug-resistant (XDR) status, defined as susceptibility to no more than two of the antimicrobial classes tested, was assigned under the hospital surveillance protocol. Risk-factor analysis was exploratory. Results: Of 243 Gram-negative isolates, 162 (66.7%) were carbapenem-resistant and 150 of these (92.6%) were designated XDR. Resistance reached 90.6% in Klebsiella pneumoniae and 83.0% in Acinetobacter baumannii, against 33.3% in Pseudomonas aeruginosa and 0% in Escherichia coli, and occurred at every infection site. No routinely recorded characteristic distinguished resistant from susceptible infection after adjustment (area under the curve 0.62). In-hospital death was associated with intensive care transfer (adjusted odds ratio 6.92, 95% confidence interval 3.33–14.38) but not with carbapenem resistance (1.14, 0.52–2.50). Of 92 carbapenem recipients, 54 (58.7%) had a carbapenem-resistant isolate, against which carbapenems are inactive, and 12 (13.0%) had a Gram-negative isolate that was neither carbapenem-resistant nor extended-spectrum β-lactamase-producing. Conclusions: At this centre, carbapenem resistance in Gram-negative HAI is endemic, could not be predicted from the routinely recorded characteristics examined, and exceeds European surveillance figures only among the Enterobacterales. No independent association with mortality was detected, although the susceptible comparison group was small. The XDR proportion was assigned under the hospital surveillance protocol and is not directly comparable with category-based estimates. Because antibiotic exposure was recorded without timing relative to culture sampling, these data support prospective audit of carbapenem prescribing rather than demonstrating missed de-escalation.